| Full Name | Aldurazyme® (laronidase) |
| Drug | Aldurazyme |
| Manufacturer | Genzyme Corporation |
| Route of Administration | Intravenous |
| Site of Care | Home or Healthcare Facility |
| Approved Indication | Adult and pediatric patients with Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I) and for patients with the Scheie form who have moderate to severe symptoms |
| Disease | Mucopolysaccharidosis I |
| Therapeutic Area | Neurology, Genetics |
| Enrollment Form Link | Enrollment Form |
| Phone Number | 800-240-9572 |
| Fax Number | 877-220-7581 |
| Product Website | aldurazyme.com/healthcare |
Nationwide Home Infusion & Nursing Network
For At-Home Infusions, Patient Training, and Patient Support
At Orsini, we have a long history of providing quality home infusion services to rare and chronic disease patients through our comprehensive nursing network. Overseen by Orsini nurse managers, this network acts as an extension of our team, leading to seamless internal communication and patient care coordination.
About Us
Highly Skilled Nursing Team
These highly skilled RNs receive disease- and therapy-specific training, developed together with our biopharma partners, from Orsini nurse case managers. Their visits are customized to fit the needs of each patient who chooses to receive in-home infusions, and we strive to foster ongoing patient-nurse relationships to maintain consistency in care. Where appropriate, our nursing network can also provide therapy self-administration training directly to patients.
Our nationwide nursing and payor coverage allows us to reach patients whenever and wherever they need care, at all stages of life, and the Orsini Nurse Support Hotline puts nursing help at the tips of patients’ and prescribers’ fingers.
Drugs with home health nursing available
| Full Name | Amondys 45™ (casimersen) |
| Drug | Amondys 45 |
| Manufacturer | Sarepta Therapeutics, Inc. |
| Route of Administration | Intravenous |
| Site of Care | Healthcare Facility |
| Approved Indication | Treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping |
| Disease | Duchenne Muscular Dystrophy (DMD) |
| Therapeutic Area | Neurology |
| Enrollment Form Link | Enrollment Form |
| Phone Number | 800-356-5034 |
| Fax Number | 877-339-4602 |
| Product Website | amondys45.com |
| Full Name | Amvuttra® (vutrisiran) |
| Drug | Amvuttra |
| Manufacturer | Alnylam Pharmaceuticals, Inc. |
| Route of Administration | Subcutaneous |
| Site of Care | Healthcare Facility |
| Approved Indication | Treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults |
| Disease | Hereditary ATTR amyloidosis (hATTR) - Polyneuropathy (PN) |
| Therapeutic Area | Neurology |
| Enrollment Form Link | Enrollment Form |
| Phone Number | 800-372-9581 |
| Fax Number | 877-349-7938 |
| Product Website | amvuttrahcp.com |
| Full Name | Berinert® [C1 esterase inhibitor (human)] |
| Drug | Berinert |
| Manufacturer | CSL Behring |
| Route of Administration | Intravenous |
| Site of Care | Home |
| Approved Indication | Treatment of acute abdominal, facial, or laryngeal hereditary angioedema (HAE) attacks in adult and pediatric patients |
| Disease | Hereditary Angioedema (HAE) |
| Therapeutic Area | Allergy & Immunology |
| Enrollment Form Link | Enrollment Form |
| Phone Number | 800-356-4252 |
| Fax Number | 847-631-6918 |
| Product Website | berinert.com/professional |
| Full Name | Cerezyme® (imiglucerase) |
| Drug | Cerezyme |
| Manufacturer | Sanofi Genzyme |
| Route of Administration | Intravenous |
| Site of Care | Home or Healthcare Facility |
| Approved Indication | Treatment of adults and pediatric patients 2 years of age and older with Type 1 Gaucher disease that results in one or more of the following conditions: anemia, thrombocytopenia, bone disease, hepatomegaly or splenomegaly |
| Disease | Gaucher Type I Disease |
| Therapeutic Area | Neurology, Genetics |
| Enrollment Form Link | Enrollment Form |
| Phone Number | 800-240-9572 |
| Fax Number | 877-220-7581 |
| Product Website | cerezyme.com/hcp |
| Full Name | Cinryze® [C1 esterase inhibitor (human)] |
| Drug | Cinryze |
| Manufacturer | Takeda Pharmaceuticals U.S.A., Inc. |
| Route of Administration | Intravenous |
| Site of Care | Home or Healthcare Facility |
| Approved Indication | Routine prophylaxis against angioedema attacks in adults, adolescents, and pediatric patients (6 years of age and older) with Hereditary Angioedema (HAE) |
| Disease | Hereditary Angioedema (HAE) |
| Therapeutic Area | Allergy & Immunology |
| Enrollment Form Link | Enrollment Form |
| Phone Number | 800-356-4252 |
| Fax Number | 847-631-6918 |
| Product Website | cinryze.com/hcp |
| Full Name | Crysvita® (burosumab-twza) |
| Drug | Crysvita |
| Manufacturer | Kyowa Kirin North America |
| Route of Administration | Subcutaneous |
| Site of Care | Home or Healthcare Facility |
| Approved Indication | The treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 6 months of age and older and FGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in adult and pediatric patients 2 years of age and older |
| Disease | Tumor-induced Osteomalacia (TIO); X-linked Hypophosphatemia (XLH) |
| Therapeutic Area | Endocrinology & Bone Specialty |
| Enrollment Form Link | Enrollment Form |
| Phone Number | 800-240-7614 |
| Fax Number | 877-793-4897 |
| Product Website | crysvitahcp.com |
| Full Name | Dojolvi® (triheptanoin) |
| Drug | Dojolvi |
| Manufacturer | Ultragenyx |
| Route of Administration | Oral or Gastrointestinal Tube |
| Site of Care | Home |
| Approved Indication | The treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD) |
| Disease | Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) |
| Therapeutic Area | Neurology, Genetics |
| Enrollment Form Link | Enrollment Form |
| Phone Number | 800-546-7102 |
| Fax Number | 877-389-5186 |
| Product Website | dojolvihcp.com |
| Full Name | Elaprase® (idursulfase) |
| Drug | Elaprase |
| Manufacturer | Takeda Pharmaceuticals U.S.A., Inc. |
| Route of Administration | Intravenous |
| Site of Care | Home or Healthcare Facility |
| Approved Indication | Patients with Hunter syndrome (Mucopolysaccharidosis II, MPS II) |
| Disease | Mucopolysaccharidosis II |
| Therapeutic Area | Neurology, Genetics |
| Enrollment Form Link | Enrollment Form |
| Phone Number | 800-240-9572 |
| Fax Number | 877-220-7581 |
| Product Website | elaprase.com/hcp |
| Full Name | Elfabrio® (pegunigalsidase alfa-iwxj) |
| Drug | Elfabrio |
| Manufacturer | Chiesi |
| Route of Administration | Intravenous |
| Site of Care | Home or Healthcare Facility |
| Approved Indication | The treatment of adults with confirmed Fabry disease |
| Disease | Fabry disease |
| Therapeutic Area | Neurology, Genetics |
| Enrollment Form Link | Enrollment Form |
| Phone Number | 833-656-1056 |
| Fax Number | 636-355-3610 |
| Product Website | hcp.elfabrio.com |
| Full Name | Evkeeza® (evinacumab-dgnb) |
| Drug | Evkeeza |
| Manufacturer | Regeneron Pharmaceuticals |
| Route of Administration | Intravenous |
| Site of Care | Home or Healthcare Facility |
| Approved Indication | Adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 12 years and older, with homozygous familial hypercholesterolemia (HoFH) |
| Disease | Homozygous Familial Hypercholesterolemia (HoFH) |
| Therapeutic Area | Cardiology |
| Enrollment Form Link | Enrollment Form |
| Phone Number | 800-645-4142 |
| Fax Number | 877-473-0199 |
| Product Website | evkeezahcp.com |
| Full Name | Exondys 51® (eteplirsen) |
| Drug | Exondys 51 |
| Manufacturer | Sarepta Therapeutics, Inc. |
| Route of Administration | Intravenous |
| Site of Care | Home or Healthcare Facility |
| Approved Indication | The treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping |
| Disease | Duchenne Muscular Dystrophy (DMD) |
| Therapeutic Area | Neurology |
| Enrollment Form Link | Enrollment Form |
| Phone Number | 800-356-5034 |
| Fax Number | 877-339-4602 |
| Product Website | exondys51.com |
| Full Name | Fabrazyme® (agalsidase beta) |
| Drug | Fabrazyme |
| Manufacturer | Sanofi Genzyme |
| Route of Administration | Intravenous |
| Site of Care | Home or Healthcare Facility |
| Approved Indication | The treatment of adult and pediatric patients 2 years of age and older with confirmed Fabry disease |
| Disease | Fabry disease |
| Therapeutic Area | Neurology, Genetics |
| Enrollment Form Link | Enrollment Form |
| Phone Number | 800-240-9572 |
| Fax Number | 877-220-7581 |
| Product Website | hcp.fabrazyme.com |
| Full Name | Kalbitor® (ecallantide) |
| Drug | Kalbitor |
| Manufacturer | Takeda Pharmaceuticals U.S.A., Inc. |
| Route of Administration | Subcutaneous |
| Site of Care | Home |
| Approved Indication | Treatment of acute attacks of hereditary angioedema (HAE) in patients 12 years of age and older |
| Disease | Hereditary Angioedema (HAE) |
| Therapeutic Area | Allergy & Immunology |
| Enrollment Form Link | Enrollment Form |
| Phone Number | 800-356-4252 |
| Fax Number | 847-631-6918 |
| Product Website | kalbitor.com/hcp |
| Full Name | Kanuma® (sebelipase alfa) |
| Drug | Kanuma |
| Manufacturer | Alexion Pharmaceuticals, a subsidiary of AstraZeneca |
| Route of Administration | Intravenous |
| Site of Care | Home or Healthcare Facility |
| Approved Indication | The treatment of patients with a diagnosis of Lysosomal Acid Lipase (LAL) deficiency |
| Disease | Lysosomal Acid Lipase Deficiency (LAL-D) |
| Therapeutic Area | Neurology, Genetics |
| Enrollment Form Link | Enrollment Form |
| Phone Number | 800-240-9572 |
| Fax Number | 877-220-7581 |
| Product Website | kanuma.com/hcp |
| Full Name | Lumizyme® (alglucosidase alfa) |
| Drug | Lumizyme |
| Manufacturer | Sanofi Genzyme |
| Route of Administration | Intravenous |
| Site of Care | Home or Healthcare Facility |
| Approved Indication | Patients with Pompe disease (GAA deficiency) |
| Disease | Pompe Disease |
| Therapeutic Area | Neurology, Genetics |
| Enrollment Form Link | Enrollment Form Link |
| Phone Number | 800-240-9572 |
| Fax Number | 877-220-7581 |
| Product Website | lumizyme.com |
| Full Name | Naglazyme® (galsulfase) |
| Drug | Naglazyme |
| Manufacturer | BioMarin Pharmaceutical Inc. |
| Route of Administration | Intravenous |
| Site of Care | Home or Healthcare Facility |
| Approved Indication | Patients with Mucopolysaccharidosis VI (MPS VI; Maroteaux-Lamy Syndrome) |
| Disease | Mucopolysaccharidosis VI |
| Therapeutic Area | Neurology, Genetics |
| Enrollment Form Link | Naglazyme Enrollment Form |
| Phone Number | 800-240-9572 |
| Fax Number | 877-220-7581 |
| Product Website | naglazyme.com |
| Full Name | Nexviazyme® (avalglucosidase alfa-ngpt) |
| Drug | Nexviazyme |
| Manufacturer | Sanofi Genzyme |
| Route of Administration | Intravenous |
| Site of Care | Home or Healthcare Facility |
| Approved Indication | The treatment of patients 1 year of age and older with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) |
| Disease | Pompe Disease |
| Therapeutic Area | Neurology, Genetics |
| Enrollment Form Link | Nexviazyme Enrollment Form Link |
| Phone Number | 800-240-9572 |
| Fax Number | 877-220-7581 |
| Product Website | nexviazyme.com |
| Full Name | Onpattro® (patisiran) |
| Drug | Onpattro |
| Manufacturer | Alnylam Pharmaceuticals |
| Route of Administration | Intravenous |
| Site of Care | Home or Healthcare Facility |
| Approved Indication | The treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults |
| Disease | Hereditary ATTR amyloidosis (hATTR) - Polyneuropathy (PN) |
| Therapeutic Area | Neurology |
| Enrollment Form Link | Onpattro Start Form |
| Phone Number | 800-690-8236 |
| Fax Number | 877-445-8481 |
| Product Website | onpattro.com |
| Full Name | Oxlumo® (lumasiran) |
| Drug | Oxlumo |
| Manufacturer | Alnylam Pharmaceuticals |
| Route of Administration | Subcutaneous |
| Site of Care | Home or Healthcare Facility |
| Approved Indication | The treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients |
| Disease | Primary Hyperoxaluria Type 1 (PH1) |
| Therapeutic Area | Nephrology |
| Enrollment Form Link | Oxlumo Enrollment Form |
| Phone Number | 800-460-5217 |
| Fax Number | 877-276-8563 |
| Product Website | oxlumo.com |
| Full Name | PEDMARK® (sodium thiosulfate injection) |
| Drug | Pedmark |
| Manufacturer | Fennec Pharmaceuticals |
| Route of Administration | Intravenous |
| Site of Care | Home or Healthcare Facility |
| Approved Indication | Reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month of age and older with localized, non-metastatic solid tumors |
| Disease | Ototoxicity associated with cisplatin |
| Therapeutic Area | Otolaryngology |
| Enrollment Form Link | Pedmark Enrollment Form |
| Phone Number | 800-385-8596 |
| Fax Number | 877-694-2545 |
| Product Website | pedmark.com |
| Full Name | Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) |
| Drug | Pombiliti & Opfolda |
| Manufacturer | Amicus Therapeutics |
| Route of Administration | Intravenous and oral |
| Site of Care | Home or Healthcare Facility |
| Approved Indication | The treatment of adult patients with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) weighing ≥40 kg and who are not improving on their current enzyme replacement therapy (ERT) |
| Disease | Pompe Disease |
| Therapeutic Area | Neurology, Genetics |
| Enrollment Form Link | Pombiliti & Opfolda Enrollment Form |
| Phone Number | 800-240-9572 |
| Fax Number | 877-220-7581 |
| Product Website | pombilitiopfolda.com |
| Full Name | Tzield® (teplizumab-mzwv) |
| Drug | Tzield |
| Manufacturer | Sanofi |
| Route of Administration | Intravenous |
| Site of Care | Home or Healthcare Facility |
| Approved Indication | Delay the onset of Stage 3 type 1 diabetes (T1D) in adults and pediatric patients aged 8 years and older with Stage 2 T1D |
| Disease | Type 1 Diabetes (T1D) |
| Therapeutic Area | Endocrinology & Bone Specialty |
| Enrollment Form Link | Tzield Enrollment Form |
| Phone Number | 800-670-5321 |
| Fax Number | 877-655-4364 |
| Product Website | tzield.com |
| Full Name | Viltepso® (viltolarsen) |
| Drug | Viltepso |
| Manufacturer | NS Pharma |
| Route of Administration | Intravenous |
| Site of Care | Home or Healthcare Facility |
| Approved Indication | The treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping |
| Disease | Duchenne Muscular Dystrophy (DMD) |
| Therapeutic Area | Neurology |
| Enrollment Form Link | Viltepso Enrollment Form |
| Phone Number | 800-759-0445 |
| Fax Number | 877-286-3620 |
| Product Website | viltepso.com |
| Full Name | Vimizim® (elosulfase alfa) |
| Drug | Vimizim |
| Manufacturer | BioMarin Pharmaceutical Inc. |
| Route of Administration | Intravenous |
| Site of Care | Home or Healthcare Facility |
| Approved Indication | Patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome) |
| Disease | Mucopolysaccharidosis IVA |
| Therapeutic Area | Neurology, Genetics |
| Enrollment Form Link | Vimizim Enrollment Form |
| Phone Number | 800-240-9572 |
| Fax Number | 877-220-7581 |
| Product Website | vimizim.com |
| Full Name | Vpriv® (velaglucerase alfa) |
| Drug | Vpriv |
| Manufacturer | Takeda Pharmaceuticals U.S.A., Inc. |
| Route of Administration | Intravenous |
| Site of Care | Home or Healthcare Facility |
| Approved Indication | Long-term enzyme replacement therapy (ERT) for pediatric and adult patients with type 1 Gaucher disease |
| Disease | Gaucher Type I Disease |
| Therapeutic Area | Neurology, Genetics |
| Enrollment Form Link | Vpriv Enrollment Form |
| Phone Number | 800-240-9572 |
| Fax Number | 877-220-7581 |
| Product Website | hcp.vpriv.com |
| Full Name | Vyepti® (eptinezumab-jjmr) |
| Drug | Vyepti |
| Manufacturer | Lundbeck |
| Route of Administration | Intravenous |
| Site of Care | Home or Healthcare Facility |
| Approved Indication | The preventive treatment of migraine in adults |
| Disease | Migraine |
| Therapeutic Area | Neurology |
| Enrollment Form Link | Vyepti Enrollment Form |
| Phone Number | 800-259-7145 |
| Fax Number | 877-892-3019 |
| Product Website | vyeptihcp.com |
| Full Name | Vyondys 53® (golodirsen) |
| Drug | Vyondys 53 |
| Manufacturer | Sarepta Therapeutics, Inc. |
| Route of Administration | Intravenous |
| Site of Care | Home or Healthcare Facility |
| Approved Indication | The treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping |
| Disease | Duchenne Muscular Dystrophy (DMD) |
| Therapeutic Area | Neurology |
| Enrollment Form Link | Vyondys 53 Enrollment Form |
| Phone Number | 800-356-5034 |
| Fax Number | 877-339-4602 |
| Product Website | vyondys53.com |